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Abstract
Transfusion-related acute lung injury (TRALI) is a serious clinical syndrome associated with the transfusion of plasma-containing blood 
components. Recently, TRALI has come to be recognized as the leading cause of transfusion-related death in the United States and United 
Kingdom. This complication typically presents as shortness of breath, hypoxemia, hypotension, fever and noncardiogeneic pulmonary edema, 
all occurring during or within 6 h after transfusion. Although the mechanism of TRALI has not been fully elucidated, it has been associated 
with human leukocyte antigen antibodies (class I, class II or neutrophil alloantigens) and with biologically active mediators in stored cellular 
blood components. Most of the donors implicated in cases of TRALI are multiparous women. Rarely diagnosed, TRALI can be confused with 
other causes of acute respiratory failure. Greater knowledge regarding TRALI on the part of clinicians could be crucial in preventing and 
treating this severe complication of blood transfusion.
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Introdution
Transfusion-related acute lung injury (TRALI) 
was recognized as a clinical entity in 1985.(1) 
Although there is no definitive consensus, TRALI 
is considered a serious complication related to the 
transfusion of plasma-containing blood compo-
nents. It is characterized by acute respiratory failure, 
bilateral pulmonary edema and severe hypoxemia 
without cardiac involvement, all occurring during 
or at ≤6 h after transfusion.(2,3)
In the United States and United Kingdom, TRALI 
is among the most common causes of transfu-
sion reactions, being considered the leading cause 
of transfusion-related morbidity and mortality in 
recent years.(2–4)
In fact, TRALI is a clinical syndrome. Although 
much has been learned about this syndrome, its 
pathogenesis, treatment and prevention remain 
little understood.
Epidemiology
The exact incidence of TRALI is unknown, and 
it is probably underdiagnosed. It is estimated to 
occur in 0.014–0.08% of all units of transfused 
allogeneic blood components or in 0.04–0.16% of 
all transfused patients.(3,5) A relatively rare complica-
tion, TRALI occurs at a ratio of 1 in 5000 transfused 
units and of 1 in 625 transfused patients. However, 
TRALI is considered the leading cause of transfu-
sion-related morbidity and mortality (Table 1).(2)
Since many clinicians, as well as some hema-
tologists working in blood banks, are not familiar 
with the syndrome, TRALI might be underdiag-
nosed. It can even be confused with other situations 
involving acute respiratory failure, such as acute 
respiratory distress syndrome (ARDS) and transfu-
sion-related circulatory overload. Therefore, the 
prevalence of TRALI could be higher than that esti-
mated above.(2,5,6)
Although the risk factors that contribute to the 
triggering of TRALI are unknown, certain serious 
clinical conditions at the moment of transfusion 
can trigger this syndrome. Notable among the prin-
cipal factors are malignant hematologic diseases 
and heart surgery.(5) The syndrome can occur in all 
age groups and is distributed uniformly between 
males and females.
All plasma-containing blood components can 
cause TRALI. The majority of the cases involve the 
use of whole blood, fresh frozen plasma, packed 
red blood cells, packed platelets and granulocytes 
collected through apheresis. Fresh frozen plasma 
is the blood product most frequently implicated. 
The clinical severity of TRALI does not appear to 
be related to the volume or type of blood compo-
nent transfused. Stored blood components are also 
implicated in the increased occurrence of TRALI.(7)
Pathophysiology
Although the exact pathological mechanism 
of TRALI is not known, and despite the fact that 
there is no consensus as to its pathogenesis, there 
is increasing evidence that this reaction can be trig-
gered by two distinct mechanisms. The traditional 
theory proposes an immunologically mediated reac-
tion through the binding of donor antibodies against 
recipient leukocyte antigens. An alternate mecha-
nism has been suggested, in which inflammatory 
molecules, predominantly lipid products originating 
from the cell degradation accumulated during the 
storage of blood cell products, are implicated in the 
triggering of TRALI through a non-immunological 
reaction.(8)
In the immunologically-mediated form of TRALI 
(immune TRALI), the antibodies of the donor are 
passively infused during the transfusion of the blood 
components.(9) These antibodies are directed against 
specific human neutrophil antigens (HNAs) or 
human leukocyte antigens (HLAs)(2) and are present, 
Table 1 – Transfusion-related acute lung injury in epidemiological reports.(2)
United Kingdom Germany Denmark France Canada (Québec)
Study period 1996–2003 1995–2002 1999–2002 1994–1998 2000–2003
TRALI cases 139 101 6 34 21
Adverse effects (%) 7 3 7 0.15 0.5
Mortality (%) 9 (24)* NR NR 20 9.5
*Including possible deaths attributed to TRALI; e NR: not reported; TRALI: transfusion-related acute lung injury.
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for the most part, in plasma-rich components, prin-
cipally those originating from multiparous donors 
(3 or more gestations), who are frequently immu-
nized against leukocyte antigens during pregnancy.(3) 
In approximately 6% of all cases of immune TRALI, 
the antibodies originate from the recipient.(2)
Once present in the recipient of the blood compo-
nents, the alloantibodies (anti-HLA or anti-HNA) 
activate the complement pathways, which results in 
the activation and sequestration of polymorphonu-
clear cells for pulmonary microcirculation.(5,9,10) The 
anti-leukocyte antibodies can also induce a direct 
response from the neutrophils, which shows that 
the activation of the complement system is not a 
prerequisite for the inducement of TRALI.(4)
The activated neutrophils present in the pulmo-
nary microcirculation generate an oxidative and 
cytotoxic response through the release of oxygen-
reactive substances and cytokines that cause 
endothelial cell damage and increased vascular 
permeability. Therefore, there is profound capillary 
leakage of fluids within the alveoli, which results in 
edema and respiratory failure.(4–6,9,10)
Most clinicians believe that TRALI is triggered by 
an immunological mechanism. However, in 11–39% 
of TRALI cases, no antibody against leukocyte anti-
gens is present either in the donor or in the recipient, 
which suggests that a non-immunological mecha-
nism can trigger the reaction. In this mechanism, 
the reaction might be triggered by the infusion of 
biologically active lipids during the transfusion of 
stored blood products, generally in patients with 
clinical complications such as malignant blood 
diseases or heart diseases.(2) Those lipids are capable 
of activating granulocytes, thereby triggering an 
oxidative process and tissue injury which together 
result in edema and respiratory failure.(6)
More recently, it has been suggested that TRALI 
is caused by two independent events. The first 
of these might be related to predisposing clinical 
factors, such as surgery, trauma and severe infection, 
the last leading to the production of inflamma-
tory mediators, thereby activating the pulmonary 
endothelium and resulting in neutrophil sequestra-
tion in the lung. The second event might involve 
the infusion of antibodies specific for neutrophils 
adhered to the lung or the infusion of biological 
response modifiers, including lipid compounds also 
capable of activating the same neutrophils.(9) Once 
activated, the neutrophils release oxygen-derived 
free radicals and toxic enzymes that injure the 
endothelial cells of the pulmonary capillaries. That 
is followed by capillary rupture, together with the 
exudation of fluids and proteins within the alveoli, 
which results in pulmonary edema.(2)
Using an experimental (ex vivo) model involving 
rat lungs, some authors(4) demonstrated that TRALI 
induced by anti-leukocyte antibodies is dependent 
on the density of specific antigens and does not 
necessarily require either the leuko-agglutinating 
properties of the antibodies or the presence of 
proteins of the complement system. Therefore, the 
antibody-mediated direct cell response contributes 
to the pathogenesis of immune TRALI. Similarly, 
the application of lipopolysaccharides and plasma 
or stored blood lipids in a rat model induces 
non-immune TRALI. Neutrophil activation therefore 
leads to the production of oxygen-reactive species. 
This appears to be an important pathological mech-
anism of TRALI and a central process in endothelial 
damage and capillary rupture.(4)
Clinical presentation
The TRALI syndrome is represented by a group 
of clinical symptoms that generally develop during 
or within 6 h after transfusion, with the manifesta-
tion of fever (increase of > 1 °C in temperature), 
tachypnea, cyanosis, dyspnea, acute hypoxemia 
with arterial oxygen tension/fraction of inspired 
oxygen < 300 mmHg and oxygen desaturation.(2,6,9,11) 
In the first hours, bilateral pulmonary edema, 
together with the progression of alveolar and inter-
stitial infiltrate without cardiogenic involvement, 
can be monitored in the first hours using radiolog-
ical exams (Figure 1).(2,12) In most patients, TRALI 
resolves within 48 h, and such patients present 
normal radiological exams within 4 days. However, 
hypoxemia and pulmonary infiltrates can persist for 
up to 7 days in some patients.(2,6) The frequency 
of those, as well as of other signs and symptoms 
observed in TRALI, are shown in Table 2.(13)
A diagnosis of TRALI is not always easily made, 
since the clinical signs of TRALI can be confused 
with those of ARDS, which is induced by factors 
other than transfusion.(2) Pulmonary autopsy of 
ARDS patients has shown extensive leukocyte infil-
tration with interalveolar and interstitial pulmonary 
edema. In addition, epidemiological studies of ARDS 
have shown that transfusion is the most common 
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cause of its genesis, which makes it possible that 
a significant number of those were severe cases of 
TRALI.(9)
According to the most recent Consensus 
Conference on TRALI, the diagnosis of that reaction is 
made in patients with the occurrence of acute respi-
ratory distress during or within 6 h after transfusion 
without any sign of circulatory overload, evidence 
of bilateral pulmonary edema and the absence of 
additional risk factors for acute respiratory failure. 
The criterion for the clinical diagnosis of TRALI is 
summarized in Chart 1. The differential diagnosis of 
patients with acute respiratory failure unrelated to 
TRALI includes transfusion-related circulatory over-
load, cardiogenic edema, allergic and anaphylactic 
transfusion reactions as well as the transfusion of 
bacteria-contaminated blood components.(2)
Although hypotension has been reported in 
many patients in clinical studies of TRALI, it is not 
a consistent finding and is generally unresponsive 
to the infusion of endovenous fluids. Although the 
majority of TRALI cases reported in the literature 
are referred to in the classic way and are consid-
ered severe, TRALI represents a variation in clinical 
severity, and milder cases have been reported,(12) 
as have atypical forms of TRALI with late onset of 
symptoms (48 h after transfusion).(2)
Laboratory testing
There is no rapid or conclusive laboratory test 
for the diagnosis of TRALI.(5) What exists, in reality, 
is merely a clinical diagnosis that is supported by 
laboratory test-based evidence.(10) Laboratory tests 
used to diagnose TRALI should be carried out when-
ever there is clinical evidence of TRALI in a recipient 
of blood components. Information concerning the 
donor can be important for the identification of 
potential donors implicated in the reaction, since 
multiparous donors and recipients of prior trans-
fusions are at high risk for the development of 
antibodies against granulocyte and lymphocyte 
antigens.(10)
In a recent study, we used immunoenzymatic 
assays to analyze the plasma of donors from the Blood 
Center of the Federal University of São Paulo.(15) We 
observed that 28 (24%) of the 118 donors evaluated 
presented anti-HLA antibodies.(15)
a b
Figure 1 - Pre-and post-transfusion X-rays of a patient with TRALI. Bilateral lung infiltrate with pulmonary edema is 
an essential criterion for the clinical diagnosis of TRALI. Radiographic discrepancies can be seen in the first hours after 
transfusion, with progression of the alveolar and interstitial infiltrate throughout the lung. Radiographic findings tend 
to be more specific than the results of physical examinations. TRALI: transfusion-related acute lung injury.
Table 2 - Symptoms associated with transfusion-related 
acute lung injury.(13)
Signs and Symptoms Frequency
Dyspnea Quite common
Hypoxemia Quite common
Bilateral pulmonary edema Quite common
Fever (increase of 1–2 °C) Quite common
Tachycardia Common
Hypotension Common
Cyanosis Common
Hypertension Rare
TRALI: transfusion-related acute lung injury.
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Samples from all the donors implicated in a 
TRALI case should be tested for the presence of 
alloantibodies,(10) generally beginning with the most 
recently transfused products. The current method 
of identifying alloantibodies is using fresh serum 
or plasma samples to carry out immunoenzymatic 
assays involving flow cytometry or immunofluores-
cence of lymphocytes.(2)
The detection of one or more alloantibodies in 
donor samples of blood components for a patient 
implicated in a TRALI case suggests that the reac-
tion was mediated immunologically. However, it is 
possible that not all of the anti-HLA antibodies or 
specific neutrophils implicated in clinically diag-
nosed TRALI cases will be identified.(5)
The gold standard for a laboratory test-based 
diagnosis of immune TRALI is concordance between 
the antibodies detected in the donor and the 
lymphocyte/granulocyte antigens of the recipient 
(positive crossmatch). However, when there is no 
such concordance (negative crossmatch), the pres-
ence of alloantibodies in the serum of the donor 
is considered strong evidence of having triggered 
TRALI. In addition, non-concordance does not 
exclude a diagnosis of TRALI, since some are cases 
of non-immune TRALI.(2)
The aforementioned diagnostic methods are 
incapable of identifying non-immune TRALI.(10)
Treatment and evolution
There is no specific treatment for TRALI. According 
to the consensus discussed at the International 
Forum,(16) the treatment of TRALI is based on the 
maintenance of the hemodynamic balance of the 
patient and on the necessity for the earliest possible 
application of ventilatory support.(5,16) In mild TRALI 
cases clinical improvement is generally achieved 
only with nasal oxygen administration. However, 
70% of the patients presenting the most severe 
form require orotracheal intubation and mechanical 
ventilation. The use of vasopressor agents can be 
indicated for the treatment of hypotension. The 
use of diuretics remains controversial and, since 
some patients benefit from the administration of 
fluids, these medications should not be used.(2,5) As 
in patients with acute respiratory failure or ARDS, 
corticosteroids, non-steroidal anti-inflamma-
tory drugs and surfactant protein, as well as other 
therapeutic agents, do not provide any benefits for 
patients with TRALI.(5,9) Unlike ARDS, TRALI gener-
ally has a good prognosis. Many patients present 
clinical improvement by 48 to 96 h after the onset 
of the reaction.(5,10) In 80% of all TRALI patients, 
there is resolution of the pulmonary infiltration 
within the first 4 days.(5) However, in a minority of 
patients, hypoxemia and pulmonary infiltrate can 
persist for more than 7 days.(6) The resolution of 
TRALI frequently occurs rapidly and does not have 
any long-term sequelae.(5,6) In spite of having a 
favorable prognosis, TRALI mortality is estimated at 
5 to 10% of the cases, which is still considered low 
when compared with ARDS, which has a mortality 
rate of approximately 40 to 50%.(5,6,10)
Preventive measures
Since the pathophysiology and etiology of TRALI 
have yet to be fully elucidated, and because there is 
no rapid diagnostic test, there are no clear recom-
Chart 1 - Criteria for the clinical diagnosis of transfusion-related acute lung injury.(2)
Definition of TRALI according to the European Haemovigilance Network
Acute respiratory failure
Bilateral pulmonary infiltrate on X-rays
Ocurrence during or within 6 h after transfusion
No evidence of transfusion-related circulatory overload
Criteria for the diagnosis of TRALI according to the Consensus Conference Committee in Toronto, 2004
Hypoxemia (PaO2/FiO2 < 300, oxygen saturation < 90% or other clinical evidence)
New ARF and no other risk factor for ARF present, including aspiration, multiple trauma, 
pneumonia, cardiopulmonary bypass, burns, toxin inhalation, pulmonary contusion, acute pancreatitis, drug 
overdose, drowning, shock and sepsis
If one or more risk factors for ARF are present, possible TRALI could be diagnosed
TRALI: transfusion-related acute lung injury; PaO2/FiO2: arterial oxygen tension/fraction of inspired oxygen; ARF: acute respiratory 
failure.
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mendations for the prevention of new TRALI cases.(2) 
However, the American Blood Bank Association 
recommends the temporary disqualification of 
donors implicated in TRALI cases until tests for 
the detection of antibodies against highly common 
antigens are carried out. Since the donors of blood 
components implicated in TRALI are generally 
multiparous women, the exclusion of these donors 
and using their plasma only for fractioning has been 
suggested. However, that would be an unreason-
able measure, principally because it would provoke 
a substantial decrease in the number of donors at 
some blood banks.(2,3,5,9,17)
As a means of preventing new TRALI cases, the 
following additional measures have recently been 
suggested: i) leukoreduction of blood components 
prior to their storage; ii) filtration of blood compo-
nents with the objective of removing antibodies, 
lipids and other biological response modifiers of the 
plasma fraction; and iii) storing products for shorter 
periods (using packed red blood cells within 14 days 
and packed platelets within 2 days) in order to avoid 
the effect of substances that accumulate during 
storage and that could induce TRALI.(9,14) 
Conclusions
Since TRALI is a complex clinical syndrome, it 
probably does not represent a simple pathogenic 
entity. The exact definition and diagnosis of TRALI 
has been impossible due to the limited under-
standing of the pathophysiological mechanisms 
involved in this reaction.(5)
Due to the relatively high rates of morbidity and 
mortality, TRALI has become one of the most serious 
transfusion-related complications today. Although 
knowledge of the clinical and pathophysiological 
presentation of TRALI has improved significantly, 
many questions remain unanswered.(2) 
The potential causes of TRALI include the passive 
infusion of anti-HLA antibodies into the recipient 
and biological response modifiers in susceptible 
individuals. This event in the pathophysiology 
of immune TRALI seems plausible but does not 
explain why TRALI can occur without the infusion 
of specific antibodies directly targeting recipient 
leukocytes or why this reaction does not occur even 
when there is an infused antibody in a patient who 
carries a specific antigen. Therefore, TRALI might be 
a multifunctional syndrome caused by at least two 
distinct clinical events.
Support therapy is the treatment recommended 
for most TRALI patients. Mechanical ventilation is 
often required, and most cases present a favorable 
evolution without any sequelae.
A better understanding of the epidemiology 
and pathophysiology of TRALI, which could be 
achieved by collecting more data and conducting 
more systematic research, could be useful for the 
implementation of new strategies aimed at lowering 
the risk for developing this potentially fatal compli-
cation among transfusion patients. In addition, 
without a clear understanding of the etiology of 
TRALI, preventive measures involving restrictions 
on donors or donated blood components might be 
inappropriate.
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